Quantcast
Last updated on April 18, 2014 at 12:36 EDT

Latest Conatus Pharmaceuticals Inc. Stories

2013-06-14 08:25:38

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined. All shares of the common stock to be sold in the offering will be offered by Conatus. Stifel and Piper Jaffray & Co. are acting...

2012-07-19 10:22:58

SAN DIEGO and EDMONTON, Alberta, July 19, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor. The objective of the trial is to determine safety, achievement and maintenance of insulin independence and to obtain preliminary data on the efficacy of emricasan to maintain adequate immunological...

2012-07-17 06:26:57

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately. Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development. "Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering...

2012-07-12 06:24:59

SAN DIEGO, July 12, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly created position, Mr. Morris will oversee the statistical design of the company's human clinical trials. "Mark provides an enormous amount of technical expertise in statistical design and analysis," said Steven J. Mento, Ph.D., President and CEO. "His broad experience in drug development including the hepatology...

2011-11-01 10:00:00

SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company's clinical development activities. "I am delighted to welcome Gary to the Conatus leadership team," said Steven J. Mento, Ph.D., President and CEO. "His broad experience in drug development including...

2011-10-25 13:00:00

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients. This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants. The top priority of Conatus is patient safety, and the Company has made the decision to halt this study. Conatus is conducting a thorough review of the available data to assess any future development of the...

2011-04-12 14:00:00

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011. Jim Scopa from MPM will join the Conatus Board of Directors. Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage...

2011-03-11 13:00:00

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the treatment of hepatitis C virus-infected patients at the 46th annual meeting of the European Association for the Study of the Liver (EASL) to be held in Berlin, Germany, on March 30 to April 3, 2011. Specifically, abstract 562 entitled: 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES...

2011-02-17 12:00:00

SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of...

2011-02-11 13:00:00

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund. Conatus will use the proceeds to advance the clinical development of CTS-1027,...